greeksoup/ stock research
Stock research / United States / ABUS / Filings

Arbutus Biopharma Corp. SEC filings

Arbutus Biopharma filed 21 documents with the SEC in the last twelve months, the latest report being the 10-Q of 12 August 2026. The latest filing, on 22 October 2026, was an 8-K: other events.

Filings in twelve months2114 of them 8-K news
Latest report10-Qfiled 12 Aug 2026
Latest filing8-K22 Oct 2026
Last results, two-day move-1.9%results filed 12 Aug 2026
New to this? How to read this page
  1. Companies file with the SEC when something happens. 10-Q and 10-K are the quarterly and annual reports; 8-K is news that cannot wait for the next report.
  2. An 8-K says which items it covers, such as results, a change at the top or a big contract. A foreign company files a 6-K instead.
  3. The results release is usually an 8-K filed the day results come out, before the 10-Q or 10-K.
  4. Every filing links to the original on EDGAR, the SEC's own site.

Twelve months of filings

by kind

Most of the filings were other company news (10). Results came out 4 times.

Each mark is one filing on the day it was filed, in rows by kind. Hover or tap a mark for the form and what it was about.

The share price around each results release

close before to close after

Over the last 4 releases the share price moved 2.8% on average in the two days around results, the most on 13 Nov 2025 (-6.6%).

13 Nov 2025-6.6%$4.84 to $4.52
23 Mar 2026+1.7%$4.24 to $4.31
13 May 2026+0.9%$4.31 to $4.35
12 Aug 2026-1.9%$4.67 to $4.58
Daily closeResults filed

Each ring marks a results filing. The move runs from the last close before the filing to the first close after it, so it covers results released before the open or after the close. Hover the line for any day's close.

What the company told investors on 8-K

14 filings

Arbutus Biopharma's 14 news filings (8-K) were mostly about other events (10) and results of operations (4).

  • Other eventsNews the company chose to file
    10 · latest 22 Oct 2026
  • Results of operationsThe quarterly results release
    4 · latest 12 Aug 2026
  • Officer or director changeSomeone joined, left or changed role at the top
    2 · latest 16 Jul 2026
  • Termination of a material agreementA large contract ended
    1 · latest 16 Jul 2026
  • Shareholder voteResults of a vote at a shareholder meeting
    1 · latest 27 May 2026
  • Material agreementA large contract or deal was signed
    1 · latest 3 Mar 2026

Each line is one kind of news, with what it means in plain words. Each square is one filing; a filing can carry more than one kind, so the squares can add up to more than the filings. The date opens the latest one on EDGAR.

How it compares

every company on the site

    The bar ranks every company on the site from the lowest on the left to the highest on the right, in three equal thirds; the small figures under it are the values where each third starts, and the black tick is the middle company. The orange dot is this company; the grey ticks are the other companies in its industry (hover or tap for names). A hatched block is companies tied at none.

    Every filing as a table

    In the last twelve months Arbutus Biopharma Corp. filed 21 documents with the SEC of the kinds listed here: 14 current reports (8-K), about 10 other events; 4 results of operations; 2 officer or director change; 1 termination of a material agreement; 1 shareholder vote; 3 quarterly reports (10-Q), 1 employee share plan registration (S-8), 1 additional proxy material (DEFA14A), 1 proxy statement (DEF 14A), 1 annual report (10-K). The latest, filed 22 October 2026: 8-K, other events. The 10-K, the 10-Qs and the proxy statement themselves, each with a link to open it, are on the documents page.

    FiledFormWhat it was aboutPeriod or event dateFiling
    22 October 20268-KOther events20 October 2026EDGAR
    21 August 20268-KOther events21 August 2026EDGAR
    12 August 202610-Qquarterly report30 June 2026EDGAR
    12 August 20268-KResults of operations12 August 2026EDGAR
    16 July 20268-KTermination of a material agreement, Officer or director change, Other events15 July 2026EDGAR
    5 June 2026S-8employee share plan registrationEDGAR
    27 May 20268-KOfficer or director change, Shareholder vote26 May 2026EDGAR
    13 May 202610-Qquarterly report31 March 2026EDGAR
    13 May 20268-KResults of operations13 May 2026EDGAR
    15 April 20268-KOther events14 April 2026EDGAR
    14 April 2026DEFA14Aadditional proxy materialEDGAR
    14 April 2026DEF 14Aproxy statement26 May 2026EDGAR
    23 March 202610-Kannual report31 December 2025EDGAR
    23 March 20268-KResults of operations23 March 2026EDGAR
    3 March 20268-KMaterial agreement, Other events3 March 2026EDGAR
    20 February 20268-KOther events17 February 2026EDGAR
    6 February 20268-KOther events2 February 2026EDGAR
    16 January 20268-KOther events15 January 2026EDGAR
    11 December 20258-KOther events11 December 2025EDGAR
    13 November 202510-Qquarterly report30 September 2025EDGAR
    13 November 20258-KResults of operations, Other events13 November 2025EDGAR
    An 8-K is what a company files within four business days of a material event; the SEC numbers the events, and the words here are the SEC's own headings, shortened.
    Read moreForm 4, Form 144, 13F and Schedule 13D and 13G have their own pages. Prospectus supplements and correspondence are not listed.